Evidence map›Paper›PMID 36382298›Full record

ArticleAsian journal of pharmaceutical sciences2022

A zwitterionic polymer-inspired material mediated efficient CRISPR-Cas9 gene editing.

Lingmin Zhang, Langyu Yang, Jionghua Huang, Sheng Chen, Chuangjia Huang, Yinshan Lin, Ao Shen, ZhouYikang Zheng, Wenfu Zheng, Shunqing Tang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian journal of pharmaceutical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. The Role of CRISPR and Its Therapeutic Applications in Glioblastoma.International journal of molecular sciences · 2026
    Review
  2. Review
  3. Review
  4. CRISPR/Cas9 systems: Delivery technologies and biomedical applications.Asian journal of pharmaceutical sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Lingmin ZhangKey Laboratory of Molecular Target & Clinical Pharmacology and the State & NMPA Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & The Third and Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China.
Langyu YangKey Laboratory of Molecular Target & Clinical Pharmacology and the State & NMPA Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & The Third and Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China.
Jionghua HuangKey Laboratory of Molecular Target & Clinical Pharmacology and the State & NMPA Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & The Third and Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China.
Sheng ChenDepartment of Biomedical Engineering, Jinan University, Guangzhou 510632, China.
Chuangjia HuangKey Laboratory of Molecular Target & Clinical Pharmacology and the State & NMPA Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & The Third and Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China.
Yinshan LinKey Laboratory of Molecular Target & Clinical Pharmacology and the State & NMPA Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & The Third and Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China.
Ao ShenKey Laboratory of Molecular Target & Clinical Pharmacology and the State & NMPA Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & The Third and Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China.
ZhouYikang ZhengDepartment of Biomedical Engineering, Jinan University, Guangzhou 510632, China.
Wenfu ZhengCAS Key Lab for Biological Effects of Nanomaterials and Nanosafety, National Center for NanoScience and Technology, Beijing 100190, China.
Shunqing TangDepartment of Biomedical Engineering, Jinan University, Guangzhou 510632, China.
Guangzhou Medical University · CNJinan University · CNNational Center for Nanoscience and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The type II prokaryotic CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 (CRISPR/Cas9) adaptive immune system is a cutting-edge genome-editing toolbox. However, its applications are still limited by its inefficient transduction. Herein, we present a novel gene vector, the zwitterionic polymer-inspired material with branched structure (ZEBRA) for efficient CRISPR/Cas9 delivery. Polo-like kinase 1 (PLK1) acts as a master regulator of mitosis and overexpresses in multiple tumor cells. The Cas9 and single guide sgRNA (sgRNA)-encoded plasmid was transduced to knockout

Indexed as

CD44CRISPR/Cas9Gene editingPLK1Zwitterionic polymers

Identifiers

PMID36382298
PMCPMC9640674
OpenAlexW4297902945

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.